(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
26 February 2009 (26.02.2009)

PCT

(10) International Publication Number
WO 2009/025618 A1

(51) International Patent Classification:
A61K 31/522 (2006.01) *A61P 25/28* (2006.01)
A61K 31/519 (2006.01)

(21) International Application Number:
PCT/SE2008/050950

(22) International Filing Date: 22 August 2008 (22.08.2008)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/957,525 23 August 2007 (23.08.2007) US
60/957,523 23 August 2007 (23.08.2007) US

(71) Applicant *(for all designated States except US)*: **ASTRAZENECA AB** [SE/SE]; S-151 85 Södertälje (SE).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: **ERIKSSON, Håkan** [SE/SE]; AstraZeneca R & D Södertälje, S-151 85 Södertälje (SE). **POEWE, Werner** [AT/AT]; Medical University Of Innsbruck, Department of Neurology, Anichstrasse 35, A-6020 Innsbruck (AT).

(74) Agent: **ASTRAZENECA AB**; AstraZeneca Intellectual Property, S-151 85 Södertälje (SE).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*

WO 2009/025618 A1

(54) Title: MIPO INHIBITORS FOR THE TREATMENT OF HUNTINGTON'S DISEASE AND MULTIPLE SYSTEM ATROPHY

(57) Abstract: The present invention relates to the use of 2-thioxo-l,2, 3, 5- tetrahydro-pyrrolo[3,2-d]pyrimidine-4-one, thioxanthine and 2- thioxo-l,2,3,7-tetrahydro-6H-purin-6-one derivatives as MPO inhibitors for the treatment of multiple system atrophy (MSA), Huntington' s disease (HD).